PCI Biotech Investor Relations Material
Latest events
Q4 2024
PCI Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from PCI Biotech Holding
Access all reports
Segment Data
Access more data
R&D expenses by
Category
Clinical studies
Pre-clinical studies
Patents
CMC and equipment
Expenses by
Financials
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's proprietary PCI technology targets tumors by non-invasively targeting PECAM-1 receptors on tumor blood vessels using light-activated prodrugs. It has been granted patent protection in the United States, European Union, and certain other jurisdictions for certain uses of its technologies and products.
Key slides for PCI Biotech Holding
Q4 2024
PCI Biotech Holding
Q4 2024
PCI Biotech Holding
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
PCIB
Country
🇳🇴 Norway